Skip to content

US · NIVFW · MEDICAL - CARE FACILITIES

NewGenIvf Group Limited (NIVFW) intrinsic value and stock valuation

$0.01as of 2026-11-21 · Mkt cap 39.34K

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

NewGenIvf Group Limited DCF and intrinsic value

InvestorsCraft values NIVFW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from NIVFW’s statements →

NewGenIvf Group Limited Graham Number

Graham Number: $387.65d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Care Facilities Bangkok, BM 10110 nivf.global

How the business is doing

Fiscal 2021–2025, USD

Revenue
$4.73M
20212025
Net income
$9.88M
20212025
Free cash flow
-$-16.68M
20212025
Total equity
$26M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$4.73M$5.43M$5.14M$5.94M$4.12M
Operating income-$-10.73M-$-1.16M$40K$400K$200K
Net income$9.88M-$-530K$130K$460K-$0.00
EPSd$49.4M-$-2.65M$1.44M$5.11M-$0.00
Operating cash flow-$-10.93M-$-8.26M-$-1.79M-$-530K$1.43M
Capital expenditure-$-5.75M-$-50K-$-70K-$-90K-$-20K
Free cash flow-$-16.68M-$-8.32M-$-1.86M-$-620K$1.42M
Total assets$32.7M$3.58M$4.49M$2.9M$1.41M
Total debt$4.86M$3.03M$330K$450K$930K
Net debt$4.11M$2.57M$280K$420K$900K
Total equity$26M-$-1.48M$3.25M$100K-$-910K
Cash and short-term investments$760K$460K$50K$30K$30K
Income statement
20252024202320222021
Revenue$4.73M$5.43M$5.14M$5.94M$4.12M
Cost of revenue$3.77M$3.61M$3.45M$4.41M$3.09M
Gross profit$960K$1.83M$1.68M$1.54M$1.02M
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$11.7M$2.99M$1.64M$1.14M$830K
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$11.7M$2.99M$1.64M$1.14M$830K
Cost and expenses$15.5M$6.59M$5.09M$5.55M$3.92M
Interest income$0.00$10K$0.00$0.00$0.00
Interest expense$620K$780K$50K$80K$90K
Depreciation and amortization$500K$210K$230K$300K$340K
Ebitda$10.8M$20K$380K$730K$590K
Operating income-$-10.73M-$-1.16M$40K$400K$200K
Total other income/expenses, net$20.5M$200K$70K-$-50K-$-40K
Income before tax$9.73M-$-960K$110K$340K$160K
Income tax expense$0.00-$-490K$0.00$210K$290K
Net income$9.88M-$-530K$130K$460K-$0.00
Weighted average shares outstanding$200K$200K$90K$90K$90K
Weighted average diluted shares outstanding$200K$200K$90K$90K$90K
Balance sheet
20252024202320222021
Cash and short-term investments$760K$460K$50K$30K$30K
Net receivables$1.07M$2.36M$520K$2.32M$750K
Inventory$340K$80K$130K$50K$40K
Total current assets$7.38M$3.17M$2.46M$2.4M$820K
Property, plant and equipment, net$2.29M$370K$450K$510K$590K
Goodwill and intangible assets$23.1M$0.00$0.00$0.00$0.00
Long-term investments$0.00$200K$0.00$0.00$0.00
Total non-current assets$25.3M$610K$2.03M$510K$590K
Total assets$32.7M$3.58M$4.49M$2.9M$1.41M
Accounts payable$780K$1.3M$170K$100K$50K
Short-term debt$490K$690K$210K$200K$660K
Deferred revenue$110K$60K$10K$1.36M$810K
Total current liabilities$2.37M$2.72M$1.12M$2.56M$2.07M
Long-term debt$4.37M$2.34M$120K$250K$260K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.37M$2.34M$120K$250K$260K
Capital lease obligations$510K$120K$330K$450K$410K
Total liabilities$6.74M$5.06M$1.24M$2.8M$2.33M
Common stock$0.00$0.00$0.00$10K$10K
Retained earnings$8.89M-$-990K-$-460K-$-590K-$-1.05M
Accumulated other comprehensive income (loss)-$-140K$20K-$-10K$10K$10K
Total equity$26M-$-1.48M$3.25M$100K-$-910K
Total investments$0.00$200K$0.00$0.00$0.00
Total debt$4.86M$3.03M$330K$450K$930K
Net debt$4.11M$2.57M$280K$420K$900K
Cash flow statement
20252024202320222021
Net income$9.73M-$-470K$130K$500K-$-140K
Depreciation and amortization$500K$210K$230K$300K$340K
Stock-based compensation$0.00$0.00$0.00$0.00$0.00
Change in working capital-$-1.6M-$-7.76M-$-2.09M$710K$730K
Accounts receivable-$-540K-$-40K$0.00$130K$60K
Inventory-$-250K$50K-$-80K-$-10K$0.00
Accounts payable-$-520K$1.13M$570K$60K-$-60K
Net cash provided by operating activities-$-10.93M-$-8.26M-$-1.79M-$-530K$1.43M
Investments in property, plant and equipment-$-4.75M-$-50K-$-70K-$-90K-$-20K
Acquisitions, net-$-1.05M$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-7.56M-$-50K-$-70K-$-69.69M-$-20K
Common stock issued$12.6M$0.00$190K$71.9M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$19M$8.68M$1.91M$70.3M-$-1.54M
Net change in cash$300K$400K-$0.00$50K-$-80K
Cash at end of period$760K$460K$50K$50K$30K
Operating cash flow-$-10.93M-$-8.26M-$-1.79M-$-530K$1.43M
Capital expenditure-$-5.75M-$-50K-$-70K-$-90K-$-20K
Free cash flow-$-16.68M-$-8.32M-$-1.86M-$-620K$1.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About NewGenIvf Group Limited

        NewGenIvf Group Limited operates as an investment holding company specializing in providing assisted reproductive technologies (ART) for couples and individuals seeking fertility solutions. The company extends its operations across Thailand, Cambodia, Hong Kong, and Kyrgyzstan. Its comprehensive suite of fertility treatments includes fundamental procedures such as in vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and embryo culture. NewGenIvf also offers crucial diagnostic and preparatory services like hormonal blood tests, screenings for infectious diseases, chromosome analysis, and hysteroscopy. Additionally, the company provides specialized sperm services, encompassing analysis, sorting, washing, and cryopreservation, alongside oocyte (egg) freezing. Beyond these core medical services, NewGenIvf facilitates surrogacy arrangements, offering essential ancillary care for surrogate mothers, including routine health check-ups, nutritional supplements, and prescribed medications. To further enhance the patient journey, the company delivers a range of supplementary services such as dietary guidance, psychological counseling, acupuncture, and professional translation interpreters. These specialized medical and support services are delivered through the company's network of dedicated clinics. Founded in 2010, NewGenIvf Group Limited is headquartered in Bangkok, Thailand.

        CEO
        Wing Fung Siu
        Employees
        87
        Beta
        -0.04

        Explore

        Frequently asked questions

        What is the intrinsic value of NewGenIvf Group Limited (NIVFW)?

        InvestorsCraft does not currently publish an intrinsic value for NIVFW. How the IC value is calculated.

        Is NIVFW undervalued?

        InvestorsCraft does not publish an undervaluation signal for NIVFW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.